# Sanofi pharmaceutical manufacturing expansion in Europe

> Developing situation record from CLSTR: https://clstr.news/situations/sanofi-pharmaceutical-manufacturing-expansion-in-europe
> Updated: 2026-10-19T10:24:06.000Z. Sources: 8. Developments: 2.

Sanofi is expanding its pharmaceutical manufacturing footprint across Europe through specialized production initiatives.

In Italy, the company is shifting the focus of its Anagni site toward rare diseases, specifically lysosomal storage disorders, while also advancing vaccine production capabilities. This move aims to maintain global competitiveness against major markets like the United States and China.

In Germany, Sanofi has commenced a 2 billion euro project to build a new insulin production facility in Frankfurt-Höchst. Designed to utilize artificial intelligence, the plant aims to secure the long-term supply of insulin for European markets and strengthen medical sovereignty. The project is supported by 400 million euros in approved state aid from German federal, state, and local authorities.

## Timeline

### 2026-10-19: Sanofi invests 2 billion euros in new insulin plant in Frankfurt

Sanofi is investing 2 billion euros to build a new, AI-enhanced insulin production plant in Frankfurt-Höchst, Germany, to secure the European insulin supply by 2032.

3 sources. https://clstr.news/cluster/sanofi-invests-2-billion-euros-in-new-insulin-plant-in-frankfurt

### 2026-09-25: Sanofi expands Anagni site focus to rare diseases

Sanofi is pivoting its Anagni site in Italy toward the production of rare disease treatments and Haemophilus influenzae vaccines to bolster regional pharmaceutical competitiveness.

5 sources. https://clstr.news/cluster/sanofi-expands-anagni-site-focus-to-rare-diseases

---
Cite as: Sanofi pharmaceutical manufacturing expansion in Europe. CLSTR, https://clstr.news/situations/sanofi-pharmaceutical-manufacturing-expansion-in-europe